Health Care · Laboratory Analytical Instruments

RVTY Revvity SEC Filings & Insider Trading Activity 2026

company
CIK 31791115 filings
S&P 500

RVTY at a glance

Revvity (RVTY, SEC CIK 31791) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on November 10, 2026, an 8-K current report on November 13, 2026 and Form 4 insider filings as recently as October 2, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 28, 2025 (FY2025), Revvity (RVTY) reported revenue of $2.9 billion (up 3.7% from FY2024) and net income of $241.2 million. Diluted EPS was $2.07.
  • As of September 30, 2026, 33 institutional investment managers tracked by SignalX reported holding Revvity (RVTY) shares worth $8.0 billion in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Gonzales Anita on October 1, 2026 of 84 shares at $155.48 per share.
  • In the last 90 days, RVTY insiders reported 0 open-market purchases ($0) and 3 open-market sales ($1.3M) on Form 4, a net sale of $1.3M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$2.9B
+3.7% vs prior year
Insiders · 90 days
0 buys · 3 sells
Net −$1.3M
13F holders
33 funds
$8.0B · −1 vs prior quarter
Latest 8-K
Nov 13, 2026
Item 7.01

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 28, 2025

Full analysis →

Management Discussion & Analysis

  • Revenue $2,856.1M in FY2025, up $101.1M (+4%) YoY; Diagnostics +5% ($68.5M), Life Sciences +2% ($32.5M)
  • Gross margin 54.8% vs 55.8%; operating margin decreased 10 bps; SG&A ratio 34.7% vs 36.1%
  • Best segment: Diagnostics revenue +5% to $1,424.9M; worst: Life Sciences margin 32.0% vs 33.4% (-139 bps), Diagnostics margin 24.2% vs 26.1% (-194 bps)
  • Operating cash flow $589.0M vs $665.0M; buybacks $820.8M; capex $73.5M; dividends $32.8M
  • Key risks: tariff impact ~$20M net on gross margin; Life Sciences Solutions goodwill ($4.5B) fair value only 10–20% above carrying value; capex planned higher in FY2026

Business Overview

  • Health science solutions provider across two segments (Life Sciences and Diagnostics), serving drug discovery through clinical diagnostics in 160+ countries
  • Notable new products in FY2025: Phenologic.AI™ deep-learning imaging module, EnVision Nexus® plate reader, NeoLSD™ 7 Plex MS/MS kit (first IVD for 7 lysosomal disorders from single blood spot), and T-SPOT.Flex™ customizable ELISPOT kit
  • AI integration accelerated across portfolio: Pin-point® base editing expanded with Profluent AI-enhanced adenine deaminase editors; EUROPattern™ Classifier 2.4 AI-enhanced IFA software; Living Image™ Synergy AI multimodal imaging platform
  • ~11,000 employees globally as of Dec 28, 2025; ~80% based outside the US; ~4,000 covered by labor union/works council agreements
  • Great Place to Work certifications achieved across India, China, Poland, US, and Brazil (Euroimmun) in 2025, with improved US scores YoY: notable cultural milestone for a company mid-transformation from PerkinElmer rebrand

Risk Factors

  • Tariffs imposed in fiscal year 2025 increased cost of revenue by ~$25M and reduced gross margin by ~$20M, primarily on European-manufactured products sold in U.S.
  • U.S. government funding uncertainty causing cautious customer spending on instrumentation and consumables across pharma, biotech, and academic segments
  • Single/limited-source suppliers for critical raw materials with multi-year contracts carrying no minimum purchase requirements, creating supply disruption risk
  • $9.0B net intangible assets on balance sheet as of December 28, 2025: impairment risk if Life Sciences or Diagnostics segments underperform
  • Substantial debt across multiple tranches (2026–2051 Notes) with covenants restricting dividends, asset sales, and M&A; loss of investment-grade rating triggers higher costs

AI summary of the RVTY 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Oct 4, 2026

Management Discussion & Analysis

  • Revenue $728.9M, up 4% YoY from $698.9M
  • Life Sciences best performer: revenue $379.6M, up 11%; Diagnostics worst: $349.3M, down 2%
  • Gross margin 57.4% vs 53.6%; operating margin 13.1% vs 11.7% YoY
  • Cash $592.8M; operating cash flow $484.5M, up from $407.0M
  • $571.2M debt repayment; near-term outlook supported by sufficient internal cash for next 12 months

Risk Factors

  • Newly highlighted AI risk: flawed algorithms, biased datasets or evolving regulation could create liability, compliance costs and reputational damage
  • Most material regulatory update: U.S. funding and regulatory changes are making customers more cautious on instrumentation and consumables
  • Near-term market risk: tariff escalation and retaliation may materially hurt results despite manufacturing, supplier and pricing mitigation
  • Financial risk: substantial debt includes variable-rate and foreign-currency obligations, increasing interest and currency exposure
  • Compliance risk: FDA or foreign regulatory failures could trigger recalls, halted distribution, fines or criminal prosecution

AI summary of the RVTY 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 13, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • Investor Day 2026 features CEO Prahlad Singh and senior management updates
  • Focus areas: key business initiatives, operational achievements and financial outlook

Item EX-99.1: Item EX-99.1

  • Investor Day outlines Revvity’s strategy for AI-enabled scientific discovery across Life Sciences and Diagnostics
  • Management reaffirmed a long-term goal of above-market growth and sustained shareholder value

Item EX-99.2: Item EX-99.2

  • Investor Day presentation highlights 2026E revenue of approximately $2.9B, with 85% recurring revenue
  • Life Sciences 2026E revenue approximately $1.5B, Diagnostics approximately $1.4B
Filed Nov 3, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Q3 revenue $729M, up from $699M, while pro forma organic growth reached 7%, indicating broad-based demand recovery
  • Adjusted EPS $1.38 versus $1.18, with adjusted operating margin expanding to 28.7% from 26.1%

Item EX-99.2: Item EX-99.2

  • China IDX divestiture removes $120 million of potential consideration from pro forma assets, including transferred liabilities and excluding contingent consideration
  • Pro forma revenue reduced $164.6 million for 2025, while continuing-operations EPS falls from $2.07 to $1.63

Item 2.02: Results of Operations and Financial Condition

  • Third-quarter results announced for period ended October 4, 2026
  • Full financial results and management commentary available in Exhibit 99.1

Item 8.01: Other Events

  • Planned sale of substantially all China Immunodiagnostics assets for up to $200 million, subject to adjustments and closing conditions
  • Definitive agreement signed July 31, 2026, signaling portfolio reshaping and exit from China IDX operations
Filed Aug 4, 2026Full analysis →

Item 8.01: Other Events

  • Planned sale of substantially all China Immunodiagnostics assets for up to $200 million, subject to adjustments and closing conditions
  • Definitive agreement signed July 31, 2026, with closing expected by end of 2027

Item EX-99.2: Item EX-99.2

  • China IDX divestiture removes $140M potential consideration from continuing operations, including transferred liabilities and excluding contingent consideration
  • Pro forma revenue reduction: $164.6M for FY2025, $42.8M for six months ended July 5, 2026

Item 2.02: Results of Operations and Financial Condition

  • Q2 fiscal 2026 results announced for quarter ended July 5, 2026
  • Full financial results and management commentary available in Exhibit 99.1

Item EX-99.1: Item EX-99.1

  • Q2 revenue $730M, pro forma revenue $711M, with 3% organic growth and adjusted EPS $1.41 versus $1.18
  • Adjusted operating margin expanded to 28.9% from 26.6%, supported by $16M of tariff-related refunds

AI summaries of RVTY 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for RVTY

Don't miss the next RVTY filing

  • Alerts as it files. A push when RVTY files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut RVTY, by share count.
  • Ask anything. An AI agent that reads every RVTY filing and answers with sources.

RVTY alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Gonzales AnitaSellOct 1, 2026$155.48
Krakowiak MaxwellSellSep 21, 2026$144.53
Vohra Tajinder SSellSep 16, 2026$140.88
MICHAS ALEXIS PGAug 25, 2026-
Goldberg Joel SGAug 14, 2026-
Goldberg Joel SGAug 14, 2026-
Singh Prahlad R.GAug 13, 2026-
Singh Prahlad R.GAug 13, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue$2.8B$2.8B$2.9B
Operating Income$300.6M$346.7M$356.6M
Net Income-$270.4M$241.2M
Op. Margin10.9%12.6%12.5%
Net Margin-9.8%8.4%
Balance Sheet
Total Assets-$12.4B$12.2B
Equity$7.9B$7.7B$7.3B
ROE-3.5%3.3%
Per Share
EPS-$2.20$2.07
Cash Flow
Operating CF-$628.3M$582.9M
CapEx$81.4M$86.6M$73.5M

Source: XBRL data in Revvity (RVTY)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate RVTY share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
RVTY shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202633$7.95B
Q2 202634$5.00B
Q1 202631$4.10B
Q4 202532$4.49B
Q3 202532$4.20B
Q2 202531$4.45B
Q1 202528$3.18B
Q4 202424$2.83B
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 245 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

RVTY filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KNov 13, 2026Analysis-
10-QNov 10, 2026Analysis
8-KNov 3, 2026Analysis-
4Oct 2, 2026--
4Sep 23, 2026--
4Sep 18, 2026--
4Aug 25, 2026--
4Aug 18, 2026--
4Aug 17, 2026--
10-QAug 11, 2026Analysis
8-KAug 4, 2026Analysis-
4Jul 22, 2026--
4Jun 17, 2026--
10-QMay 12, 2026Analysis
4May 11, 2026-
4May 11, 2026-
4May 11, 2026-
4May 11, 2026-
4May 11, 2026-
4May 11, 2026-
4May 11, 2026-
4May 11, 2026-
4May 11, 2026-
8-KMay 5, 2026Analysis-
8-KMay 1, 2026Analysis-

Related Health Care companies

All Health Care →

RVTY SEC filings: frequently asked questions

Are RVTY insiders buying or selling?

In the last 90 days, Revvity (RVTY) officers, directors and 10% owners reported no open-market purchases and 3 open-market sales worth $1.3 million by 3 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold RVTY stock?

As of September 30, 2026, the largest Revvity (RVTY) holders among the 13F filers tracked by SignalX were T. Rowe Price Group ($2.0 billion), BlackRock ($1.2 billion), Vanguard Capital Management LLC ($1.1 billion), Vanguard Portfolio Management LLC ($725.1 million), State Street Corp ($668.3 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was RVTY's revenue in fiscal year 2025?

For the fiscal year ended December 28, 2025 (FY2025), Revvity (RVTY) reported revenue of $2.9 billion (up 3.7% from FY2024) and net income of $241.2 million. Diluted EPS was $2.07. The figures come from the XBRL data in the 10-K.

What are the main risks in RVTY's latest 10-K?

In the 10-K filed February 24, 2026, Revvity (RVTY) flagged: Tariffs imposed in fiscal year 2025 increased cost of revenue by ~$25M and reduced gross margin by ~$20M, primarily on European-manufactured products sold in U.S. U.S. government funding uncertainty causing cautious customer spending on instrumentation and consumables across pharma, biotech, and academic segments. (AI summary of the Risk Factors section.)

What did RVTY report in its latest 8-K?

Revvity (RVTY) filed an 8-K on November 13, 2026 reporting Item 7.01 (Regulation FD Disclosure). Investor Day 2026 features CEO Prahlad Singh and senior management updates.

What are the latest RVTY SEC filings?

Revvity (RVTY) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on November 10, 2026, an 8-K current report on November 13, 2026 and a Form 4 insider filing on October 2, 2026.

What is RVTY's SEC CIK number?

Revvity (RVTY)'s SEC Central Index Key (CIK) is 31791. EDGAR lists every RVTY filing under that number.

Ask anything about RVTY

The research agent reads RVTY's filings, financials, insider trades and 13F holders, then answers with sources.